Showing 2611-2620 of 5831 results for "".
- New from Thermi: Meet the Arvati Platformhttps://practicaldermatology.com/news/new-from-thermi-meet-the-arvati-platform/2457624/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequency platform that powers a range of Thermi procedures including ThermiTight, ThermiRase, ThermiSmooth Face a
- FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-ortho-derms-resubmission-of-nda-for-duobrii-lotion-for-plaque-psoriasis/2457630/The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15,
- Latest on Compounding: FDA Proposes to Strike Three Bulk Drug Substances from Listhttps://practicaldermatology.com/news/latest-on-compounding-fda-proposes-to-strike-three-bulk-drug-substances-from-list/2457632/The FDA has issued a
- FDA Nod for Ortho Derm's Acne Lotion Altrenohttps://practicaldermatology.com/news/fda-nod-for-ortho-derms-acne-lotion-altreno/2457635/The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Ortho Dermatologic’s Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients aged 9 and up. Altreno is expected to be
- Wake Forest Researchers: #2 in Probiotic Advancementhttps://practicaldermatology.com/news/wake-forest-researchers-2-in-probiotic-advancements/2457638/Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the body’s ability to produce short-chain fatty acids (SCFAs). “Short-chain fa
- FDA Adds Four Tropical Diseases to Priority Review Voucher Programhttps://practicaldermatology.com/news/fda-adds-four-tropical-diseases-to-priority-review-voucher-program/2457639/The FDA announced the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases.
- Revision Skincare Launches DEJ Eye Cream, DEJ Face Creamhttps://practicaldermatology.com/news/revision-launches-dej-eye-cream-dej-face-cream/2457648/Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses
- Pulse Biosciences: First Patient Treated in BCC Studyhttps://practicaldermatology.com/news/pulse-biosciences-first-patient-treated-in-bcc-study/2457653/The first patient has been treated in a clinical study to evaluate Nano-Pulse Stimulation (NPS) from Pulse Biosciences, Inc. for
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an